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Although fibroblast growth factor 23 (FGF23) acting through
its receptor Klotho-FGFR1c decreases parathyroid hormone
expression, this hormone is increased in chronic kidney
disease despite an elevated serum FGF23. We measured
possible factors that might contribute to the resistance of
parathyroid glands to FGF23 in rats with the dietary adenine-
induced model of chronic kidney disease. Quantitative
immunohistochemical and reverse transcription–PCR analysis
using laser capture microscopy showed that both Klotho and
FGFR1 protein and mRNA levels were decreased in
histological sections of the parathyroid glands. Recombinant
FGF23 failed to decrease serum parathyroid hormone levels
or activate the mitogen-activated protein kinase signaling
pathway in the glands of rats with advanced experimental
chronic kidney disease. In parathyroid gland organ culture,
the addition of FGF23 decreased parathyroid hormone
secretion and mRNA levels in control animals or rats with
early but not advanced chronic kidney disease. Our results
show that because of a downregulation of the Klotho–FGFR1c
receptor complex, an increase of circulating FGF23 does not
decrease parathyroid hormone levels in established chronic
kidney disease. This in vivo resistance is sustained in
parathyroid organ culture in vitro.
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Fibroblast growth factor 23 (FGF23) is secreted by osteocytes
and osteoblasts in response to hyperphosphatemia and
1,25(OH)2 vitamin D and exerts its effect on its receptor,
the Klotho–FGFR1c heterodimer, in the kidney where it
inhibits the expression of NaPi2 and the 25(OH) vitamin D
1a(OH)ase, CYP27B1.1,2 The action of FGF23 on the kidney
results in phosphaturia and a decreased serum 1,25(OH)2
vitamin D level, which acts to correct serum Pi. FGF23 also
exerts its effect on the Klotho–FGFR1c complex in the
parathyroid to decrease parathyroid hormone (PTH) gene
expression and secretion in rats with normal kidney function,
as well as in vitro in rat and bovine tissue.3,4 Surprisingly, in
chronic kidney disease (CKD), there are markedly elevated
levels of both FGF23 and PTH.5 This finding implies
resistance of parathyroids to FGF23 in renal failure. The
increase in serum FGF23 is found in early CKD6 and, at least
in stage 4 CKD,7 it precedes the decrease in serum 1,25(OH)2
vitamin D, which was found in a large cohort of CKD
patients to be the earliest change in mineral metabolism
parameters.8 The decrease in serum 1,25(OH)2 vitamin D is
considered to be an important factor in the pathogenesis of
secondary hyperparathyroidism.9 The increased FGF23 levels
in renal failure patients correlate with the progression of renal
failure,10,11 the prediction of the development of secondary
hyperparathyroidism,12 as well as mortality in patients
starting dialysis.13 Therefore, it is important to understand
the mechanisms that prevent the parathyroid from respond-
ing to high levels of FGF23 in uremia. In this study, we show
that the resistance to FGF23 in parathyroids of rats with
experimental CKD correlates with the downregulation of
parathyroid Klotho–FGFR1 expression and FGF23 signaling.
RESULTS
Klotho and FGFR1 protein and mRNA levels are decreased in
parathyroids of rats with adenine high Pi-induced CKD
Rats fed an adenine high-Pi diet had a fourfold increase in
serum creatinine at 2 weeks and a 10-fold increase at 6 weeks,
accompanied by matching increases in serum urea (Table 1).
Serum Pi was increased at 2 weeks and even more so at 6
weeks. Serum PTH was fourfold increased at 2 weeks and
18-fold increased at 6 weeks together with an increase in
serum FGF23 levels (Table 1). Parathyroid staining with
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Ki-67, a marker of cell proliferation, was increased both at 2
and 6 weeks of the adenine high-Pi diet (Figure 1a and b).
Parathyroid cell proliferation increased after 3 days of the
diet. Intriguingly, at CKD 1 week, Ki-67 staining was
transiently reduced to similar levels as in parathyroids of
control rats (Figure 1a and b). Therefore, in this model,
parathyroid cell proliferation is increased at 3 days, is arrested
at 1 week, and is evident again at 2 and 6 weeks of the diet.
Immunohistochemistry (IH) of the parathyroids of rats
fed the adenine high-Pi diet for 2 weeks showed an increase
in Klotho and a decrease in FGFR1 (Figure 2a and b). There
was no significant change in parathyroid VDR and CaR at 2
weeks (Figure 2a and b). Importantly, at 6 weeks, there was a
decrease in Klotho and FGFR1 levels, as well as a decrease in
VDR and CaR (Figure 2a and b). The parathyroid PTH
protein did not change, despite the marked hyperparathyr-
oidism (Figure 2a and b; Table 1). To study the correlation
between parathyroid cell proliferation (Ki-67), Klotho, and
FGFR1 expression, we stained consecutive parathyroid
sections of rats fed the adenine high-Pi diet for 3 days, and
for 1 and 2 weeks. Ki-67 was increased at 3 days but not at 1
week and increased at 2 weeks (Figure 2c and d) as before
(Figure 1). Klotho was increased at 1 and 2 weeks, whereas
FGFR1 was already decreased at 3 days (Figure 2c and d).
These results show that in experimental CKD at 6 weeks,
there is a decrease in FGFR1 and Klotho protein levels that
may contribute to the resistance of the parathyroid to FGF23.
Laser capture microscopy of equivalent areas of parathyr-
oid sections (Figure 3a) from control rats and rats fed the
adenine high-Pi diet for 6 weeks showed a decrease in both
Klotho and FGFR1 mRNAs (Figure 3b). PTH mRNA levels
were increased in CKD rats at 6 weeks (Figure 3b). Therefore,
both Klotho and FGFR1 protein and mRNA levels were
decreased in these rats with advanced experimental CKD
and secondary hyperparathyroidism. We then studied the
response of the parathyroids of CKD rats to FGF23.
Administered FGF23 does not decrease PTH expression at
6 weeks of experimental CKD both in vivo and in vitro
FGF23 administered intraperitoneally led to a decrease
in serum PTH in control rats as previously described
(Figure 4a).3 FGF23 also decreased serum PTH in CKD rats
at 2 weeks (Figure 4a). However, FGF23 had no effect on
serum PTH in CKD rats at 6 weeks (Figure 4a). FGF23 binds
to its receptor, the Klotho–FGFR1c heterodimer, to activate
the mitogen-activated protein kinase (MAPK) pathway and
thereby induces the expression of Egr1 (early growth response
gene 1).1,3 To study signal transduction after FGF23 in
parathyroids of CKD rats, we measured Egr1 mRNA levels.
To do this, we developed a novel methodology, whereby we
anesthetized rats, exposed the two parathyroid glands, and
applied FGF23 topically on one gland and a medium to the
contralateral parathyroid as a control in the same rat. After
30 min, we extracted the RNA from each microdissected
gland and quantified mRNA levels. FGF23 led to a twofold
induction of Egr1 mRNA in control rat parathyroid
glands compared with vehicle-treated contralateral glands
(Figure 4b). In contrast, there was no induction of Egr1
mRNA by FGF23 in rats fed the adenine high-Pi diet for 6
weeks (Figure 4b). These experiments show that FGF23 does
not activate the MAPK pathway in rats fed the adenine high-
Pi diet for 6 weeks and subsequently does not decrease serum
PTH in vivo.
We then studied the effect of FGF23 in vitro using rat
parathyroid glands maintained in organ culture for 2 h.
FGF23 added to the culture medium led to a decrease in PTH
secreted into media by parathyroid glands from control and
2-week CKD rats, but not from 6-week CKD rats (Figure 5a).
FGF23 also decreased PTH mRNA levels in both control and
2-week CKD rats but not in 6-week CKD rats (Figure 5b).
The effect of FGF23 aside, it is noteworthy that the
parathyroids of CKD rats that were cultured with control
medium secreted more PTH and had higher PTH mRNA
levels after 2 h of organ culture compared with control rats
(Figure 5b). The increased PTH expression in CKD
parathyroids occurred despite being maintained in normal
culture medium in vitro. Importantly, the decrease in Klotho
and FGFR1 mRNA in parathyroids of 6-week CKD rats
Table 1 | Serum creatinine, urea, calcium, phosphate, and PTH
levels in control and CKD rats
Control 2 Weeks 6 Weeks P-value
Creatinine (mmol/l) 19±2 80±16 225±12 o0.0001
Urea (mmol/l) 7.8±0.3 32.4±2.5 39±2.1 o0.0001
Calcium (mmol/l) 2.43±0.14 2.21±0.11 2.12±0.1 NS
Phosphorus (mmol/l) 2±0.004 2.76±0.17 4.3±0.12 o0.0001
PTH (pg/ml) 207±14 908±161 3764±621 o0.0001
FGF23 (pg/ml) 205±37 552±70 2802±366 o0.0001
Abbreviations: CKD, chronic kidney disease; NS, not significant; PTH, parathyroid
hormone.
Values are presented as mean±s.e.m. (n=4).
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Figure 1 |Parathyroid cell proliferation in experimental
chronic kidney disease (CKD) rats. (a) Immunohistochemistry
(IH) for Ki-67 as a marker of cell proliferation in parathyroid
sections from rats fed a control or adenine high-Pi diet for the
indicated duration. (b) Ariol quantification of Ki-67 staining as in a
presented as mean±s.e.m. from 3–4 rats in each group. *Po0.05
compared with control.
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(Figure 3b) was also evident in the glands analyzed at the
termination of incubation in vitro (Figure 5c). Therefore, the
parathyroids of CKD rats maintain the increase in PTH
expression and decrease in Klotho and FGFR1 mRNA levels
of secondary hyperparathyroidism ex vivo at least for the 2 h
studied here and thus their resistance to FGF23.
DISCUSSION
FGF23 exerts its effect on the parathyroid through its
receptor, Klotho–FGFR1c, to activate the MAPK pathway
and decrease PTH expression. However, in CKD, there are
high levels of both FGF23 and PTH. It was important
therefore to understand why in CKD the high levels of FGF23
do not efficiently suppress PTH production and secretion.
We now report that there is a decrease in parathyroid gland
Klotho and FGFR1 mRNA and protein levels in advanced
experimental CKD. These changes may contribute to the
resistance of the parathyroid to the high levels of FGF23 in
CKD. Accordingly, recombinant FGF23 did not decrease PTH
expression in rats fed an adenine high-Pi diet for 6 weeks as
opposed to control rats and rats with 2 weeks experimental
CKD. Similarly, the parathyroid glands from rats with
advanced CKD failed to respond in vitro to FGF23, as
opposed to the glands from control rats and rats with early
CKD.
To study the resistance of the parathyroid to FGF23, we
used a rat model of adenine-induced CKD for short term at 2
weeks and for long term at 6 weeks of the diet. The CKD
model induced secondary hyperparathyroidism that was
greater at 6 than at 2 weeks. We used computerized
quantification of Ki-67, Klotho, FGFR1, CaR, VDR, and
PTH protein levels in paraffin-embedded parathyroid
sections of control and CKD rats. Parathyroid cell prolifera-
tion as measured by quantification of Ki-67 staining was
increased to the same degree at 2 and 6 weeks. Interestingly,
there was already higher cell proliferation at 3 days but not at
1 week. At 3 days of the diet, serum creatinine had already
increased 2.5-fold, which was maintained at 1 week when
serum PTH levels were increased sixfold.14 A similar
phenomenon was described by others using the 5/6
nephrectomy CKD model, in which it was suggested that
cell proliferation was restricted to the first days of experi-
mental CKD.15 However, they did not report longer time
intervals. Our findings show that proliferation resumes after
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Figure 2 |Ki-67, Klotho, FGFR1, VDR, CaR, and parathyroid hormone (PTH) proteins in parathyroid glands of chronic kidney disease
(CKD) rats. (a) Immunohistochemistry (IH) of Klotho, FGFR1, VDR, CaR, PTH, and IgG as control of parathyroid sections from control, 2,
and 6-week CKD rats. (b) Ariol quantification of IH as in a for four rats in each group. Results are mean±s.e.m., *Po0.05 compared with
control; #Po0.05 compared with 2-w AHP. (c) IH of Ki-67, Klotho, and FGFR1 in consecutive parathyroid sections from control, 3-day-,
and 1- and 2-week CKD rats. (d) Ariol quantification of IH as in c for Klotho and FGFR1. Data for Ki-67 are included in Figure 1b. Results are
mean±s.e.m., for 3–5 rats in each group; *Po0.05 compared with control.
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the first week of adenine high Pi-induced CKD. The IH of
parathyroid glands from control and 6-week CKD rats
showed reduced levels of Klotho and FGFR1, as well as CaR
and VDR. The reduction in parathyroid CaR and VDR in
CKD has been widely reported.16,17 Although at 6 weeks of
the diet, cell proliferation was increased, whereas FGFR1 and
Klotho levels were decreased (Figure 2), the downregulation
of the FGF23 receptor complex is not directly related to active
cell proliferation because the changes in FGFR1, Klotho, and
Ki-67 occur at different time points.
The decrease in Klotho and FGFR1 protein levels is
accompanied by a decrease in Klotho and FGFR1 mRNA
levels, as detected in parallel sections by laser-captured rat
parathyroid tissue of 6-week CKD rats. Laser capture
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Figure 2 |Continued.
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microscopy allows the analysis of the parathyroid and not of
the surrounding tissue. PTH mRNA levels were increased in
6-week CKD rats, indicating the active synthesis of the
hormone, which is then rapidly translated and secreted as
evidenced by the finding that there is no change in PTH
protein staining in parathyroid cells. Depletion of hormone
stores when there is excess stimulus to the gland is
found in other endocrine organs, such as the b-cell in
diabetes mellitus type 2.18,19 In the parathyroids of 2-week
CKD rats, there was an increase in Klotho protein but a
decrease in FGFR1 expression. The finding that Klotho was
increased at 2 weeks may explain the response of the
parathyroid to administered FGF23 in early CKD in vivo and
in vitro. The mechanism by which parathyroid Klotho
expression is regulated in CKD is not known. It is known
that Klotho mRNA levels in bovine parathyroid cells are
inversely correlated to serum calcium.20
Consistent with the decrease in the Klotho–FGFR1
complex expression in parathyroids in advanced CKD, they
also failed to respond to recombinant FGF23 both in vivo and
in vitro at the levels of PTH secretion and gene expression.
The failure of parathyroids to respond to administered
FGF23 in CKD in vivo was reflected in mRNA levels of Egr1,
a marker of MAPK activation, which were not increased after
FGF23.1,3 We measured Egr1 mRNA after the topical
application of FGF23 to one parathyroid gland, whereas the
contralateral gland was used as a control. This methodology
allows the maintenance of a physiological milieu and the
study of the control and test parathyroid in the same rat. We
were able to conclude that FGF23, which led to a twofold
induction of Egr1 mRNA in control rats, was ineffective in
inducing Egr1 in parathyroids of 6-week CKD rats. This
would prevent the effect of FGF23 on PTH gene expression.
Glands from 6-week CKD rats secreted higher amounts of
PTH in vitro in organ culture, despite removal from their
uremic surrounding corresponding to the high serum PTH
levels in vivo. Moreover, there was a progressive increase in
PTH mRNA levels in the parathyroid organ cultures from
CKD rats corresponding to the severity of the CKD and to
PTH mRNA levels in vivo.14 In contrast, Klotho and FGFR1
mRNA levels progressively decreased with CKD in vitro as in
vivo. Thus, characteristics of the parathyroid in vivo are
sustained in vitro, at least for the 2 h studied, despite being
removed from the uremic environment and maintained in
normal medium. These include both basal expression of PTH
and the failure to respond to FGF23. Therefore, the decreased
Klotho-FGFR1 and signal transduction, and increased PTH
expression are inherent to the parathyroid gland. These
changes in secondary hyperparathyroidism may be the result
of prolonged changes in any of the parameters of mineral
metabolism, such as serum Pi, calcium, vitamin D, FGF23,
and perhaps PTH itself, as well as uremic toxins.21 The
limited viability of glands in culture precludes the study of a
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Figure 3 |Klotho and FGFR1 mRNA levels are decreased and
parathyroid hormone (PTH) mRNA increased in the
parathyroids of rats with chronic kidney disease (CKD) at 6
weeks. (a) Histological section of rat parathyroid tissue before
and after laser capture showing the defined area excised for RNA
extraction. (b) Klotho, FGFR1, and PTH mRNAs and b-actin mRNA
as control measured by quantitative reverse transcription–PCR
from control and 6-week CKD rats. Results are presented as fold
change, mean±s.e.m. from four rats with three areas analyzed
from each rat. *Po0.05.
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Figure 4 | Fibroblast growth factor 23 (FGF23) decreases
serum parathyroid hormone (PTH) in control and 2-week
chronic kidney disease (CKD) rats but not in 6-week CKD rats
and increases Egr1 mRNA in control but not in 6-week CKD
rats. (a) Serum PTH levels 1 h after injection of FGF23 or vehicle
(phosphate-buffered saline, PBS) into control, 2-week and 6-week
CKD rats. Results are presented as mean±s.e.m. (n¼ 4), *Po0.05.
(b) Egr1 induction. Parathyroid glands from control and 6-week
CKD rats were exposed and FGF23 was topically applied to one
gland of each rat and control medium to the other gland for
30 min. Quantitative reverse transcription–PCR was performed for
Egr1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA from RNA extracted from single glands. Egr1 induction is
presented as mean±s.e.m. of the increase in Egr1 mRNA in the
FGF23-treated gland compared with the contralateral untreated
gland. *Po0.05, n¼ 4–5 rats.
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direct effect of prolonged changes in uremic toxins on the
resistance of the parathyroid to FGF23 in vitro.
In summary, in advanced CKD, resistance of the
parathyroid to FGF23 is associated with a decrease in
Klotho-FGFR1 expression both in mRNA and protein levels.
As a result, the high FGF23 levels characteristic of advanced
CKD fail to signal through the MAPK pathway to increase
Egr1 mRNA and decrease PTH (Figure 6). The resistance of
the parathyroid to FGF23 in CKD contributes to the
secondary hyperparathyroidism of CKD. In addition,
FGF23 decreases 1,25(OH)2 vitamin D levels, which correlate
with increased serum PTH.10,22 Of interest, specific deletion
of the VDR in the parathyroid of mice with normal kidney
function leads only to a moderate increase in serum PTH
levels.2 Therefore, in CKD, secondary hyperparathyroidism is
caused by a number of factors functioning in concert. These
are at least high serum phosphate, decreases in parathyroid
CaR, VDR, and Klotho–FGFR proteins, resistance to FGF23,
and decrease in serum 1,25(OH)2 vitamin D.
MATERIALS AND METHODS
Experimental animals
Adult male Sabra rats (weighing 175–200 g) were fed a control diet
or a 0.75% adenine, high-phosphorus (1.5%) diet23 for the
indicated time periods to induce CKD and secondary hyperpar-
athyroidism. Serum calcium, Pi, creatinine, and urea were measured
in the study groups (control rats, short-term CKD, and long-term
CKD). PTH was measured both before and 1 h after i.p. injection of
4 mg/kg mouse recombinant FGF23 with the R179Q proteolysis-
resistant mutation24 (R&D Systems, Minneapolis, MN, USA, catalog
no. 2629-FG-025), or control carrier, phosphate-buffered saline
(n¼ 4 for each group at each time point). Phosphate-buffered saline
was injected daily i.p. into all rats for 2 days before the actual
experiment to familiarize the rats with the procedure. After 2 or 6
weeks on the diet, microdissected parathyroid glands were removed
under ketamine–xylazine anesthesia for ex vivo experiments. In
parallel, parathyroid glands were removed from control rats.
Parathyroid glands were placed on filter membranes and incubated
in cell culture media at 37 1C with constant rocking,3 with or
without (n¼ 4 pairs from each group) recombinant mouse FGF23
(100 ng/ml).
In some experiments, parathyroid glands of ketamine-anesthe-
tized rats were exposed. FGF23 was applied topically to one gland
and control medium to the contralateral parathyroid gland for
30 min. FGF23 (1mg/ml) or vehicle (medium) was soaked in
Whatmann paper, which was placed on the gland. RNA was then
extracted from each microdissected gland. Quantitative reverse
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Figure 5 | Fibroblast growth factor 23 (FGF23) decreases
serum parathyroid hormone (PTH) and PTH mRNA levels in
parathyroid organ cultures from control and 2-week chronic
kidney disease (CKD) rats but not in 6-week CKD rats. Pairs of
parathyroid glands from control, 2-week or 6-week CKD rats were
incubated in culture media without (vehicle) or with FGF23 for 2 h.
(a) PTH levels in culture media, presented in semilogarithmic
scale. *Po0.05 compared with glands from control rats; #Po0.05
compared with vehicle-treated glands, n¼ 4–8. (b) PTH mRNA
levels analyzed by quantitative reverse transcription–PCR for PTH
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in
parathyroid glands as in a. (c) Klotho and FGFR1 mRNA levels in
vehicle-treated glands as in a from control, 2-week and 6-week
CKD rats. Results in b and c are represented as fold change,
mean±s.e.m. (n¼ 4–8), *Po0.05.
Normal
Pi
CaR
VD VDR
klotho
FGFR1
CaR
VDR
klotho
FGFR1
FGF23
ESRD
Egr1
PTH
PTH
PTH
PTH
PTH
PTH
PTH
PTH
PTH
PTH
Egr1
Ca2+
Pi
VD
FGF23
Ca2+
Figure 6 |Model for the regulation of parathyroid hormone
(PTH) expression by Pi, Ca2þ , vitamin D, and fibroblast
growth factor 23 (FGF23) in normal physiology and end-stage
renal disease (ESRD). When there is normal renal function, Pi
increases serum PTH, and Ca2þ , 1,25(OH)2 vitamin D, and FGF23
decrease serum PTH by exerting an effect on their respective
receptors. The Pi sensing mechanism is not known. In ESRD, the
high Pi and low 1,25(OH)2 vitamin D lead to an increase in serum
PTH. The decrease in parathyroid VDR and CaR also contributes to
the lack of response to circulating 1,25(OH)2 vitamin D and Ca
2þ .
There are very high FGF23 levels in ESRD, which fail to suppress
PTH secretion because of a downregulation of the Klotho-FGFR1
heterodimer and signal transduction through mitogen-activated
protein kinase (MAPK). Together, these changes in Pi, Ca2þ ,
1,25(OH)2 vitamin D, and their receptors, as well as the FGF23
receptor, result in secondary hyperparathyroidism.
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transcription–PCR was performed for Egr1and control genes. All
animal experiments were approved by the Hadassah Hebrew
University Animal Care and Use Committee.
Biochemistry
Serum/medium rat PTH (Immutopics, San Clemente, CA, USA,
catalog no. 60-2500) and FGF23 (Kainos Lab, Tokyo, Japan) were
measured by enzyme-linked immunosorbent assay. The increased
serum FGF23 levels in the CKD rats were also shown using a
c-terminal FGF23 Elisa kit (Immutopics, San Clemente, CA, USA,
catalog no. 60-6300). Serum calcium, phosphate, creatinine, and
urea levels were assayed using appropriate kits (QuantiChrom
DICA-500, DIPI-500, DICT-500 and DIUR-500; BioAssay Systems,
Hayward, CA, USA).
Immunohistochemistry and its quantification
Rat parathyroid glands were excised and fixed in 4% formaldehyde,
embedded in paraffin, and 4 mm sections were prepared. After
rehydration, antigens were retrieved by autoclave (120 1C for 3 min)
with 20 mM citric acid buffer (pH¼ 6; for PTH, Klotho, FGFR1, and
VDR), EDTA (pH¼ 8; Zymed Laboratories, San Francisco, CA,
USA, for CaR), or 100 mM glycine (pH¼ 9; for Ki-67). Immunos-
taining was performed overnight at 4 1C using the following primary
antibodies diluted in Cas block (Zymed Laboratories): VDR (1:100;
Santa Cruz Biotechnology, Santa Cruz, CA, USA, catalog no. sc-
1009), PTH (1:100; Abd Serotec, Oxford, UK, catalog no. 7170-
6216), Ki-67 (1:200; Biocare Medical, Concord, CA, USA, catalog
no. CM137A), CaR (1:500; Novus Biologicals, Littleton, CO, USA,
catalog no. NB120-19347), FGFR1 (1:100; Santa Cruz Biotechnol-
ogy), and Klotho 1:100 (Kyowa Hakko Kogyo, Tokyo, Japan). Slides
were incubated with the appropriate horseradish-peroxidase-con-
jugated secondary antibodies and stained by exposure to DAB
chromogen (Dako, Glostrup, Denmark), followed by counter-
staining with hematoxylin. Light hematoxylin staining was needed
to define nuclei and to facilitate some of the quantifications, for
example Ki-67. Representative microscopic images are shown.
Immunostaining was quantified with an automated system (Ariol,
Genetix, New Milton, Hampshire, UK).
Ariol was programmed to identify the spectrum of brown
staining and ignore all other colors, including the purple shades of
the nuclear hematoxylin and eosin staining. Quantification was as
follows for all but the Ki-67 staining: assignment of a threshold
intensity value for positive staining; assignment of threshold value
for background staining (in such a manner that would include all
cells but not intercellular space); and calculation of the ratio
between the areas corresponding to these two values (positive area/
total tissue area). This method of calculation was in perfect
agreement with a variation that included a term for the actual
intensity (positive area intensity/total area). For Ki-67, calculation
was determined by positive nuclei/total number of nuclei (which
was in excellent agreement with positive nuclei/total area of nuclei
and positive nuclei/total tissue area). All parathyroid glands
(control, short-, and long-term uremia) were blocked together
on the same slide to eliminate differences in staining intensity
among slides.
Parathyroid tissue recovery by laser capture microdissection
and RNA extraction
Parathyroids from formalin-fixed paraffin-embedded sections were
laser microdissected using a PALM Microlaser System (Zeiss,
Oberkochen, Germany). RNA was extracted from 2–3 separate areas
of identical size from each parathyroid section using peqGold
TriFast (peqlabs Biotechnologie, Erlangen, Germany) supplemented
with glycogen. cDNA was synthesized using a High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA,
USA) and PCR analysis was preformed with GoTaq Green PCR
Master Mix (Promega, Madison, WI, USA).
Real-time PCR
RNA was analyzed by quantitative reverse transcription–PCR for
PTH, Klotho, FGFR1, Egr1, and control mRNAs. Real-time PCR was
performed using an ABI Prism 7900 Sequence Detection System
(Applied Biosystems) and SYBR Green Mix (Applied Biosystems).
Primers (Table 2) were designed using Primer Express software
version 2.0 (Applied Biosystems) to include exon–exon junctions
and/or span large intronic sequences to prevent amplification of
genomic DNA. Amplicon specificity was ascertained by melting
curve analysis and length evaluation was ascertained by ethidium
bromide staining of agarose gels.
Statistical analysis
Results were analyzed by one-way analysis of variance with post hoc
Bonferroni’s pairwise comparisons. PTH serum levels after admin-
istration of FGF23 were log-transformed and adjusted to preinjec-
tion values by means of a general linear model (SPSS 15.0; SPSS Inc.,
Chicago, IL, USA). Two-tailed P-values o0.05 were considered
statistically significant. Results are expressed as mean±s.e.m.
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